Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial.

Cancer Med · 2023 · PMC10652308 · PMID 37840530

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an unfavorable trendno p-value reported

A stratified Cox model yielded a HR of 1.60 (95% CI: 0.78, 3.27) in Arm A and 1.53 (95% CI: 0.75, 3.15) in Arm B compared to SOC, indicating an unfavorable trend for the abemaciclib arms. 3.4 Safety Treatment‐emergent adverse events (TEAEs) occurred in >99% of the treated patients ( n = 98).

also in 30 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.